tiprankstipranks
Roche Holding AG (CH:ROP)
:ROP
Want to see CH:ROP full AI Analyst Report?

Roche Holding AG (ROP) Price & Analysis

83 Followers

ROP Stock Chart & Stats

CHF355.10
CHF5.00(1.41%)
At close: 4:00 PM EDT
CHF355.10
CHF5.00(1.41%)

Bulls Say, Bears Say

Bulls Say
Clinical EfficacyFenebrutinib demonstrated roughly half the relapse rate versus the comparator and showed consistent reductions in brain lesions and progression measures, indicating meaningful clinical benefit.
Label Expansion PotentialA label that permits switching from aromatase inhibitor monotherapy could substantially expand the giredestrant-eligible population, and additional switch data could support such an indication.
Market Opportunity In Breast CancerGiredestrant targets the majority of hormone receptor–positive, HER2‑negative breast cancer patients and appears better tolerated than standard therapy, creating potential for broad adjuvant uptake.
Bears Say
Hepatic Safety RiskElevated liver enzymes and cases meeting biochemical Hy's law in another trial point to potential hepatotoxicity that may require additional monitoring or restrictive labeling.
Mortality Safety SignalA higher count of fatal cases in the fenebrutinib arm compared with the comparator represents a serious safety signal that could limit regulatory approval and clinician adoption.
Regulatory And Evidence HurdlesSafety concerns combined with the need for definitive randomized studies for combination regimens create regulatory and reimbursement risks that could delay broader use.

Roche Holding AG News

ROP FAQ

What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was CHF243.90 and its highest was CHF374.90 in the past 12 months.
    What is Roche Holding AG’s market cap?
    Roche Holding AG’s market cap is CHF287.02B.
      When is Roche Holding AG’s upcoming earnings report date?
      Roche Holding AG’s upcoming earnings report date is Feb 04, 2027 which is in 190 days.
        How were Roche Holding AG’s earnings last quarter?
        Roche Holding AG released its earnings results on Jul 23, 2026. The company reported CHF10.85 earnings per share for the quarter, beating the consensus estimate of CHF10.33 by CHF0.52.
          Is Roche Holding AG overvalued?
          According to Wall Street analysts Roche Holding AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Roche Holding AG pay dividends?
            Roche Holding AG pays a Annually dividend of CHF9.8 which represents an annual dividend yield of 2.66%. See more information on Roche Holding AG dividends here
              What is Roche Holding AG’s EPS estimate?
              Roche Holding AG’s EPS estimate is 9.97.
                How many shares outstanding does Roche Holding AG have?
                Roche Holding AG has 702,562,700 shares outstanding.
                  What happened to Roche Holding AG’s price movement after its last earnings report?
                  Roche Holding AG reported an EPS of CHF10.85 in its last earnings report, beating expectations of CHF10.33. Following the earnings report the stock price went up 5.144%.
                    Which hedge fund is a major shareholder of Roche Holding AG?
                    Currently, no hedge funds are holding shares in CH:ROP
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Roche Holding AG

                      Roche Holding AG is a prominent global entity primarily active in the pharmaceutical and diagnostics industries. Its extensive operations encompass numerous countries, including key markets such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside a broader international presence. The company's pharmaceutical division is dedicated to developing and marketing a diverse range of medicinal products. These treatments target various therapeutic areas like oncology, neuroscience, infectious diseases, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory conditions. Additionally, their portfolio addresses specific ailments such as anemia, cancer, dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation. In the diagnostics sector, Roche supplies advanced in-vitro tests utilized for detecting and monitoring a wide array of diseases, including cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. They also provide crucial diagnostic instruments and reagents to healthcare facilities. Furthermore, Roche is engaged in a research partnership with Synlogic, Inc., focused on identifying a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). This well-established organization, founded in 1896, maintains its corporate headquarters in Basel, Switzerland.

                      Roche Holding AG (ROP) Earnings & Revenues

                      ROP Company Deck

                      ROP Earnings Call

                      Q2 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The call conveyed strong operational and financial momentum (core operating profit +10%, margin expansion, robust cash flow) combined with substantial pipeline and regulatory momentum (5 FDA priority reviews, 80% Phase III success YTD, multiple product launches/CE marks, and strategic diagnostics M&A). Headwinds were acknowledged and specific: China diagnostics pricing reform, weaker respiratory season, currency translation effects, net debt increase from dividends/timing, competitive pressures (biosimilars) and some impairments. Overall, the positive operational and pipeline developments materially outweigh the challenges, and management maintained confident guidance (mid-single-digit sales growth, high-single-digit core EPS growth) while flagging manageable near-term risks.View all CH:ROP earnings summaries

                      ROP Stock 12 Month Forecast

                      Average Price Target

                      CHF352.06
                      ▼(-0.86% Downside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"229":"CHF229","332":"CHF332","435":"CHF435","280.5":"CHF280.5","383.5":"CHF383.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":434.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF434.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":352.05555555555554,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF352.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[229,280.5,332,383.5,435],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,328.8,336.9307692307692,345.0615384615385,353.1923076923077,361.32307692307694,369.45384615384614,377.5846153846154,385.7153846153846,393.84615384615387,401.9769230769231,410.10769230769233,418.23846153846154,426.36923076923074,{"y":434.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,328.8,330.5888888888889,332.3777777777778,334.1666666666667,335.9555555555556,337.74444444444447,339.53333333333336,341.3222222222222,343.1111111111111,344.9,346.68888888888887,348.47777777777776,350.26666666666665,{"y":352.05555555555554,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,328.8,321.2,313.6,306,298.40000000000003,290.8,283.2,275.6,268,260.4,252.8,245.2,237.60000000000002,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":252.958,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":249.464,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.472,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.916,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.211,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.823,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":318.453,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":343.972,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.123,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 84,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.8,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Novartis AG
                      Lonza Group Ltd
                      Alcon
                      Sandoz Group Ltd
                      Galderma Group AG
                      Popular Stocks